-transparent.png){kind=logo}
In diabetic patients with hyperlipoproteinemia type IV the monohexosyl ceramide concentration in blood plasma is significantly elevated. This augmentation can be attributed to an increased monohexosyl ceramide content of the BLDL plasma fraction. In contrast, the di-, tri-, the tetrahexosyl ceramide levels remain within normal limits. In normolipidemic diabetics of comparable age, sex, and weight classes and of comparable metabolic control no elevations of glycolipid fractions could be found. However, patients with primary hyperlipoproteinemia type IV show an increase of monohexosyl ceramide concentrations in blood plasma. Therefore, the augmentation of monohexosyl ceramide levels in plasma of hyperlipidemic diabetic patients seems rather a metabolic consequence of hyperlipoproteinemia than of diabetes per se. A clearcut explantation for the monohexosyl ceramide elevations in the studied groups cannot be given at present time.
G J Kremer, and
W Atzpodien, and
E Schnellbacher
September 1978,
Metabolism: clinical and experimental,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
July 1982,
Ophthalmology,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
May 1963,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
G J Kremer, and
W Atzpodien, and
E Schnellbacher
December 1983,
Scandinavian journal of clinical and laboratory investigation,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
January 1967,
The Journal of the Egyptian Medical Association,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
February 1986,
Acta ophthalmologica,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
January 1972,
Annals of clinical laboratory science,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
May 1985,
Archives of biochemistry and biophysics,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
December 1982,
Diabetes,
G J Kremer, and
W Atzpodien, and
E Schnellbacher
March 1983,
Acta neurologica Scandinavica,
